Get connected to independent support organizations and resources to support your treatment journey
Program essentials
Enrollment form
Spanish enrollment form
CareASSIST patient overview flashcard
Online resources*
Our Care Managers can provide guidance around additional support resources.
HealthCare.gov
YOU ARE NOW LEAVING SanofiCareASSIST.com
Sanofi does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. Sanofi makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi necessarily endorse such website and/or database.
Medicaid.gov
YOU ARE NOW LEAVING SanofiCareASSIST.com
Sanofi does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. Sanofi makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi necessarily endorse such website and/or database.
Medicare.gov
YOU ARE NOW LEAVING SanofiCareASSIST.com
Sanofi does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. Sanofi makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi necessarily endorse such website and/or database.
Patient Advocate Foundation
YOU ARE NOW LEAVING SanofiCareASSIST.com
Sanofi does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. Sanofi makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi necessarily endorse such website and/or database.
Patient Advocate Network Foundation
YOU ARE NOW LEAVING SanofiCareASSIST.com
Sanofi does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. Sanofi makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi necessarily endorse such website and/or database.
American Cancer Society
YOU ARE NOW LEAVING SanofiCareASSIST.com
Sanofi does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. Sanofi makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi necessarily endorse such website and/or database.
Cancer Support Community
YOU ARE NOW LEAVING SanofiCareASSIST.com
Sanofi does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. Sanofi makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi necessarily endorse such website and/or database.
National Comprehensive Cancer Network®
YOU ARE NOW LEAVING SanofiCareASSIST.com
Sanofi does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. Sanofi makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi necessarily endorse such website and/or database.
CancerCare
YOU ARE NOW LEAVING SanofiCareASSIST.com
Sanofi does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. Sanofi makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi necessarily endorse such website and/or database.
FindHelp.org
YOU ARE NOW LEAVING SanofiCareASSIST.com
Sanofi does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. Sanofi makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Sanofi necessarily endorse such website and/or database.
*This listing is provided as a resource only and does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources on this topic may be available and should be investigated. Sanofi does not review or control the content of non-Sanofi websites.
INDICATION
ELITEK is indicated for the initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. ELITEK is indicated only for a single course of treatment.
IMPORTANT SAFETY INFORMATION
WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS
•Hypersensitivity Reactions: ELITEK can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue ELITEK in patients who experience a serious hypersensitivity reaction.
•Hemolysis: Do not administer ELITEK to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue ELITEK in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting ELITEK.
•Methemoglobinemia: ELITEK can result in methemoglobinemia in some patients. Immediately and permanently discontinue ELITEK in patients developing methemoglobinemia.
•Interference with Uric Acid Measurements: ELITEK enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in prechilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection.
CONTRAINDICATIONS
ELITEK is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase. ELITEK is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD).
ADVERSE REACTIONS
Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy, are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase.
USE IN SPECIFIC POPULATIONS
•Pregnancy: Consider the benefits and risks of ELITEK and possible risks to the fetus when prescribing ELITEK to a pregnant woman
•Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with ELITEK and for 2 weeks after the last dose
